SEC Form 4 · accession 0000914475-15-000057
NEUROCRINE BIOSCIENCES INC · NBIX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Darin Lippoldt
Officer — Chief Legal Officer
Period of report
Feb 3, 2015
Accepted (ET)
Feb 5, 2015 · 5:12 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000914475
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF1,F2 | — | Feb 3, 2015 | A | 25,000 | A | — | — | Common Stock | 25,000 | 25,000 | D |
| Stock OptionF3 | $32.99 | Feb 3, 2015 | A | 30,000 | A | — | Feb 3, 2025 | Common Stock | 30,000 | 30,000 | D |
Explanation of responses
- F1Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock.
- F2Performance Restricted Stock Units ("PRSU") will vest upon the Company obtaining FDA approval of a New Drug Application. The vesting provisions of these PRSUs are exclusive of the elagolix program.
- F3Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 3, 2015 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.